Fabtech Technologies ipo date, Share Price Target Tomorrow, 2025, 2026, 2030
Fabtech Technologies is an Indian company that helps to make medicines and healthcare products. It provides services that follow international standards and takes care of everything from planning and buying equipment to setting it up and checking that it works properly. The company provides clean air systems, pure water systems, and machines for making medicines like liquids, tablets, and creams. It operates in many countries and manages projects efficiently through its digital system, FabAssure.
- 1 What is Fabtech Technologies Ltd IPO?
- 2 Fabtech Technologies IPO Details
- 3 Fabtech Technologies Share Price Target Tomorrow (Listing day price)
- 4 Fabtech Technologies Share Price Target 2025
- 5 Fabtech Technologies share price Target 2026
- 6 Share price Target 2027
- 7 Share price Target 2028
- 8 Share price Target 2029
- 9 Fabtech Technologies share price Target 2030
- 10 Share price Target 2040
- 11 Share Price Target 2050
- 12 Should I buy Fabtech Technologies stock?
- 13 Fabtech Technologies earnings results (Financials)
- 14 Is Fabtech Technologies stock good to buy? (bull case & bear case)
- 15 Fabtech Technologies IPO Promoter Holding
- 16 Objects of the Issue (Fabtech Technologies IPO Objectives)
- 17 Fabtech Technologies ipo gmp
- 18 Conclusion
- 19 FAQs
What is Fabtech Technologies Ltd IPO?
Fabtech Technologies was established in 2002 in Mumbai by Aasif Ahsan Khan. It helps to make medicines by providing complete engineering services for the pharmaceutical and healthcare industries. The company does everything from designing and buying equipment to installing, testing, and certifying facilities. It works with different types of medicines like liquids, solids, and creams. It aims to make medicines cheaper and available to more people, helping millions of lives with more than 400 employees and working in over 60 countries.
Fabtech Technologies IPO Details
| IPO Date | September 29, 2025 to October 1, 2025 |
| Listing Date | 07 Oct 2025 |
| Face Value | ₹10 per share |
| Price Band | ₹181 to ₹191 per share |
| Minimum Investment | ₹13575 |
| Lot Size | 75 Shares |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 3,23,92,239 shares |
| Share Holding Post Issue | 4,44,52,239 shares |
This company is growing and doing well in business. It has lowered its debt, increased its profits, and maintained strong results for its investors. The company’s sales and income are going up, its savings and assets are growing, and its borrowings have come down. The main problem is that it takes more time to get payments from customers. Overall, it is in a good and safe position, but it can do even better.
| Day | Minimum Price (Rs) | Maximum Price (Rs) |
| Tomorrw | -21 | +72 |
It is a leading company that provides complete engineering services for the pharmaceutical industry. It manages everything, ranging from understanding what the client needs and studying diseases, supplying equipment, managing the project, installing systems, testing them, and getting necessary approvals. The company has completed projects in many countries and is known for delivering complex projects with high quality and efficiency. In 2025, its share price target would be ₹430, as per stock market analysts.
According to stock market analysts, its share price would be between ₹141 to ₹430 in 2025.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 141 | 430 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| October | 167 | 258 |
| November | 141 | 379 |
| December | 290 | 430 |
It gets most of its equipment from other companies instead of making everything itself. This saves money and avoids big investments in machines or factories. The company focus on important work like designing facilities, running projects, checking quality, delivering equipment, and helping clients with this approach. It gets equipment on time and at a lower cost by working with trusted suppliers. Its teams and partnerships also help keep high quality and make the most out of each project. In 2026, its share price target would be ₹967, as per stock market analysts.
Its share price would be between ₹442 to ₹967 in 2026, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2026 | 442 | 967 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 442 | 538 |
| February | 474 | 575 |
| March | 510 | 600 |
| April | 521 | 625 |
| May | 532 | 654 |
| June | 542 | 684 |
| July | 557 | 700 |
| August | 578 | 725 |
| September | 620 | 747 |
| October | 652 | 790 |
| November | 678 | 825 |
| December | 788 | 967 |
It uses a project management system software, ‘FabAssure’, to handle all parts of its projects. The system links every task to one central network, so the company can easily track progress, monitor work, and solve problems fast. It helps teams work together better, keeps everything clear, and lets the company stay in control throughout the project. In 2027, its share price target would be ₹1439, as per stock market analysts.
According to stock market analysts, its share price would be between ₹921 to ₹1439 in 2027.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2027 | 921 | 1439 |
It has done projects in many parts of the world, including developing countries. The company deals with local problems like political issues, supply delays, and a lack of workers by planning carefully and checking for risks. It makes sure its projects follow local rules while keeping high international standards. This helps projects run smoothly, finish on time, and stay strong for the future. In 2028, its share price target would be ₹1972, as per stock market analysts.
Its share price would be between ₹1370 to ₹1972 in 2028, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2028 | 1370 | 1972 |
It uses an easy and organised process to get new projects. Its sales and marketing teams contact clients in good ways and carefully check opportunities. This helps the company keep a steady number of projects, even though building pharmaceutical facilities takes time and costs a lot. It grows by its projects and makes sure each one meets client needs and gives value from beginning to end. In 2029, its share price target would be ₹2450, as per stock market analysts.
According to stock market analysts, its share price would be between ₹1887 to ₹2450 in 2029.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2029 | 1887 | 2450 |
The company is experienced in making different types of medicines, including liquids, tablets, capsules, injections, ointments, and inhalers. It works with many products, from special cancer medicines to regular over-the-counter drugs. This experience helps the company handle complicated manufacturing processes efficiently while keeping high quality. In 2030, its share price target would be ₹, as per stock market analysts.
Its share price would be between ₹2410 to ₹2990 in 2030, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2030 | 2410 | 2990 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 2410 | 2535 |
| February | 2441 | 2578 |
| March | 2474 | 2632 |
| April | 2490 | 2674 |
| May | 2532 | 2700 |
| June | 2558 | 2735 |
| July | 2584 | 2768 |
| August | 2630 | 2790 |
| September | 2657 | 2833 |
| October | 2678 | 2857 |
| November | 2700 | 2925 |
| December | 2784 | 2990 |
The company’s profits have kept rising, which shows it controls expenses and works in an efficient way. Its steady growth proves that the company is expanding its business while still giving good quality results. It invests in new technology, moves into more regions, and gives trusted services to clients in the pharmaceutical and healthcare fields, making its global image stronger. In 2040, its share price target would be ₹6780, as per stock market analysts.
According to stock market analysts, its share price would be between ₹6220 to ₹6780 in 2040.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2040 | 6220 | 6780 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 6220 | 6358 |
| February | 6257 | 6385 |
| March | 6280 | 6400 |
| April | 6300 | 6435 |
| May | 6332 | 6480 |
| June | 6358 | 6523 |
| July | 6370 | 6578 |
| August | 6414 | 6600 |
| September | 6457 | 6647 |
| October | 6480 | 6680 |
| November | 6558 | 6725 |
| December | 6590 | 6780 |
It has good experience in working with many types of medicines like liquids, solids, and semisolids. It handles products such as tablets, capsules, injections, ointments, and inhalers. The company works on both advanced drugs, like cancer medicines, and regular over-the-counter products. Because of this wide experience, it manages even complex projects while keeping the quality high. In 2050, its share price target would be ₹11600, as per stock market analysts.
Its share price would be between ₹10300 to ₹11600 in 2050, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2050 | 10300 | 11600 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 10300 | 10447 |
| February | 10384 | 10490 |
| March | 10400 | 10535 |
| April | 10422 | 10578 |
| May | 10447 | 10635 |
| June | 10482 | 10674 |
| July | 10500 | 10725 |
| August | 10547 | 10889 |
| September | 10674 | 11000 |
| October | 10841 | 11147 |
| November | 10992 | 11328 |
| December | 11258 | 11600 |
Should I buy Fabtech Technologies stock?
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 141 | 430 |
| 2026 | 442 | 967 |
| 2027 | 921 | 1439 |
| 2028 | 1370 | 1972 |
| 2029 | 1887 | 2450 |
| 2030 | 2410 | 2990 |
| 2040 | 6220 | 6780 |
| 2050 | 10300 | 11600 |
It is a growing company in the pharma engineering field. It has been earning more money and profit, has many projects in hand, which gives it a strong position in the market. The company also has low debt and good experience with international projects. But there are some risks; it needs more money to run projects, delays in payments, dependence on a few big clients, changes in material prices, and global or legal issues. So, investors should think about both the growth and these risks before buying the stock.
Fabtech Technologies earnings results (Financials)
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
| Sales + | 121 | 257 | 194 | 226 |
| Expenses + | 110 | 225 | 169 | 191 |
| Operating Profit | 11 | 32 | 25 | 35 |
| OPM % | 9% | 12% | 13% | 16% |
| Other Income + | 2 | 4 | 10 | 6 |
| Interest | 2 | 3 | 5 | 3 |
| Depreciation | 0 | 2 | 2 | 2 |
| Profit before tax | 11 | 31 | 28 | 36 |
| Tax % | 29% | 25% | 22% | 24% |
| Net Profit + | 8 | 23 | 22 | 27 |
| EPS in Rs | — | — | — | — |
| Dividend Payout % | 0% | 0% | 0% | 0% |
Is Fabtech Technologies stock good to buy? (bull case & bear case)
Bull Case:
- It increased its revenue by 54% in FY25.
- The company improved its profit after tax (PAT) margin by 310 basis points (bps) to 8.86%, showing better efficiency in operations.
- It has an ROCE of 22.82%, meaning it uses its capital effectively.
- The total debt-to-equity ratio is only 1.04%, showing the company has very little debt.
- It gave a dividend of ₹2.00 per share in May 2025, showing it shares its profits with its investors.
Bear Case:
- A large part of revenue comes from a few big clients, so losing one could affect business.
- Most revenue comes from large projects, so delays or cancellations could hurt financial stability.
- Company has high debtors of 156 days.
Fabtech Technologies IPO Promoter Holding
Aasif Ahsan Khan, Hemant Mohan Anavkar, Aarif Ahsan Khan and Manisha Hemant Anavkar are the promoters of the company.
| Promoter Holding Pre Issue | 94.61% |
| Promoter Holding Post Issue | — |
Objects of the Issue (Fabtech Technologies IPO Objectives)
- ₹1,270.00 crore will be used to fund the company’s working capital requirements.
- ₹300.00 crore will be used for pursuing inorganic growth initiatives through acquisitions.
- The rest will be used for the company’s general corporate purposes.
Fabtech Technologies ipo gmp
| Date | IPO GMP | Gain |
| 27 Sep | ₹35 | 18.32% |
Conclusion
It is a well-known Indian company that helps make medicines and healthcare products. It manages everything from designing to providing equipment, installing systems, and testing facilities. The company makes clean air systems, pure water systems, and machines for producing medicines like liquids, tablets, capsules, ointments, and more. The company is growing, earning higher profits, and has low debt, but investors should also consider risks like depending on a few big clients, needing lots of money for projects, delays in payments, changes in material costs, and global or legal problems before investing.
